Japanese CRO JCL Bioassay Sales And Profits Increase
This article was originally published in PharmAsia News
Japanese contract research organization JCL Bioassay announced April 30 results for FY2008. The company achieved a record ¥2.48 billion in sales, a 7 percent increase. The company's business profit increased by 40.6 percent to ¥502 million, regular profit increased by 32.3 percent to ¥437 million, and net profit increased by 11.3 percent to ¥259 million. Bioanalysis service accounts for 80 percent of JCL Bioassay's sales. For the fiscal year 2009, JCL Bioassay estimates sales, business profit and regular profit increases by 3.5, 11.2 and 3.8 percent, respectively. The company cites a continuous outsourcing trend in pharmaceutical companies. (Click here for more - Japanese language
You may also be interested in...
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.
GSK is transferring technology to make its malaria vaccine antigen to Bharat Biotech and by 2029 will also transfer rights to supply the vaccine to WHO-approved immunization programs. The deal is expected to improve access via lower cost of the vaccine for such programs
Rules covering OTC medical devices, herbals and online activities have been added for the first time to the Irish Pharmaceutical Healthcare Association's Self-Care Advertising Code.